<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of severe refractory atopic dermatitis (eczema) in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of severe refractory atopic dermatitis (eczema) in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of severe refractory atopic dermatitis (eczema) in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy G Berger, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1474176844"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In adults, atopic dermatitis (AD) may present as a chronic, persistent form of childhood AD; a relapsing form of childhood AD that had apparently resolved; or, less commonly, as "adult-onset" AD [<a href="#rid1">1-5</a>]. However, the diagnosis of adult-onset AD should be made with caution, as numerous skin conditions may present as an eczematous dermatitis in adulthood  (<a class="graphic graphic_table graphicRef116291" href="/z/d/graphic/116291.html" rel="external">table 1</a>).</p><p>This topic will discuss the evaluation and management of severe AD in adults. The pathogenesis, clinical manifestations, diagnosis, and management of AD in adults and children are discussed separately. The treatment of severe AD in children is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1726.html" rel="external">"Management of severe atopic dermatitis (eczema) in children"</a>.)</p><p></p><p class="headingAnchor" id="H375508998"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>It is estimated that 2 to 5 percent of adults have atopic dermatitis (AD) [<a href="#rid6">6-10</a>]. In a Finnish, population-based study, the 12-month prevalence of AD in adults ≥30 years was 10 percent [<a href="#rid11">11</a>]. In the United Kingdom, a prevalence of approximately 9 percent has been estimated in persons older than 75 years [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H575168414"><span class="h1">CLINICAL PHENOTYPES IN ADULTS</span><span class="headingEndMark"> — </span>In adults, atopic dermatitis (AD) may present as [<a href="#rid1">1-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A chronic, persistent form of childhood AD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A relapsing form of childhood AD that had apparently resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Adult-onset" atopic dermatitis – Adult-onset AD is the less common form. Whether it is a distinct phenotypic variant of AD is unclear [<a href="#rid12">12</a>]. In most cases, it appears before the age of 40 years and is often a recalcitrant, difficult-to-treat condition [<a href="#rid6">6,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic chronic eczematous eruption of aging – Chronic eczematous eruption of aging is defined as new-onset, atopic-like dermatitis presenting in patients over 50 years of age with no history of childhood AD [<a href="#rid14">14</a>].</p><p></p><p>Patients may incorrectly report AD as first appearing in adulthood for several reasons [<a href="#rid13">13</a>]: their childhood AD was so mild that it is not remembered; in adults from sunny, humid, tropical climates (Southeast Asia and Latin America), AD may appear when they move to drier temperate zones; and AD may appear or be exacerbated by pregnancy. </p><p class="headingAnchor" id="H1144165441"><span class="h1">PATIENT EVALUATION</span></p><p class="headingAnchor" id="H514197684"><span class="h2">Is the diagnosis of atopic dermatitis correct?</span><span class="headingEndMark"> — </span>When evaluating an adult patient with <strong>new-onset</strong> dermatitis that is persistent and relapsing, the diagnosis of atopic dermatitis (AD) should be made with caution, as a variety of skin conditions may present as an eczematous dermatitis in adulthood  (<a class="graphic graphic_table graphicRef116291" href="/z/d/graphic/116291.html" rel="external">table 1</a>). The most important clinical features that suggest the diagnosis of AD are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location</strong> – The skin eruption begins in or affects anatomic sites classically involved by adult AD (hand eczema  (<a class="graphic graphic_picture graphicRef116272" href="/z/d/graphic/116272.html" rel="external">picture 1</a>), eyelid eczema  (<a class="graphic graphic_picture graphicRef116273" href="/z/d/graphic/116273.html" rel="external">picture 2</a>), nipple eczema, and flexural eczema  (<a class="graphic graphic_picture graphicRef64525 graphicRef116281" href="/z/d/graphic/64525.html" rel="external">picture 3A-B</a> and <a class="graphic graphic_picture graphicRef55375" href="/z/d/graphic/55375.html" rel="external">picture 4</a>)) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesion morphology</strong> – The morphology is characteristic of AD, with lichenified plaques, excoriations, and a propensity for secondary staphylococcal infection  (<a class="graphic graphic_picture graphicRef116283 graphicRef116284 graphicRef116286 graphicRef116287" href="/z/d/graphic/116283.html" rel="external">picture 5A-D</a>). Of note, in individuals with darkly pigmented skin, erythema may appear dark brown or violaceous instead of pink or red, as typically seen in patients with lighter complexions. Dry skin may have a whitish or ashy color, and lichenified areas typically appear hyperpigmented.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopy</strong> – Other atopic conditions (asthma, allergic rhinitis, etc) are present.</p><p></p><p>However, the clinical diagnosis of AD in adults may be challenging due to multiple reasons, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis coexisting with other eczematous dermatitis</strong> – AD can coexist with an exogenous dermatitis, such as allergic contact dermatitis, seborrheic dermatitis, or photodermatitis. (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncommon morphology</strong> – Young adult AD patients can develop lesions with a nummular morphology [<a href="#rid16">16</a>]. However, adult males also develop classic nummular dermatitis not associated with AD that presents with weepy plaques starting on the extremities (usually one leg)  (<a class="graphic graphic_picture graphicRef96163" href="/z/d/graphic/96163.html" rel="external">picture 6</a>) and then generalizing. (See  <a class="medical medical_review" href="/z/d/html/13666.html" rel="external">"Nummular eczema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis mimickers</strong> – Allergic contact dermatitis, seborrheic dermatitis, psoriasis, drug eruptions, bullous pemphigoid, dermatitis herpetiformis, and cutaneous T cell lymphoma may mimic AD in adults. A high index of suspicion, repeated biopsies, and appropriate laboratory testing should be performed to rule out these conditions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonspecific (idiopathic) eczematous dermatitis</strong> – Older adult patients with chronic idiopathic pruritus may develop a nonspecific eczematous dermatitis, the so-called "eruption of senescence" or idiopathic "chronic eczematous eruption of aging" [<a href="#rid17">17</a>]. They usually have associated xerosis and pruritus that is disproportionately severe compared with the skin eruption. This nonspecific dermatitis may result from age-related barrier failure and immune imbalance, which lead to a predominately T helper type 2 (Th2) reaction pattern in the skin, similar to AD [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H1898771814"><span class="h2">When to biopsy</span><span class="headingEndMark"> — </span>A skin biopsy should be performed in adult patients presenting with recalcitrant, eczematous dermatitis. Various skin conditions that present in adulthood as an eczematous dermatitis  (<a class="graphic graphic_table graphicRef116291" href="/z/d/graphic/116291.html" rel="external">table 1</a>) have histopathologic features of acute or chronic eczema similar to those of AD. If, after appropriate treatment, the eruption is not significantly improved, repeat biopsies and additional tests may be required to rule out or confirm certain diagnoses, such as scabies, mycosis fungoides, bullous pemphigoid, or cutaneous T cell lymphoma. A biopsy will not be helpful in differentiating AD from allergic contact dermatitis. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a> and  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H767425549"><span class="h2">Potential diagnostic pitfalls</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history of atopy may be misleading </strong>– Since the prevalence of atopy exceeds 20 percent in the general population of many resource-abundant nations, a positive family history for atopic disease can lead to a mistaken diagnosis of AD in an adult presenting with an eczematous eruption. Once the diagnosis of AD is placed in the patient's medical record, further diagnostic considerations may be ignored. As an example, a patient with cutaneous T cell lymphoma may not be biopsied, or appropriate patch testing may not be performed in a patient with allergic contact dermatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy of previously treated skin</strong> – A potential biopsy diagnostic pitfall is the misdiagnosis of dermatitis treated with potent topical steroids, which may show residual dermal inflammation in the absence of the typical epidermal changes of spongiosis and hyperkeratosis that characterize AD and other eczemas. In these cases, the biopsy report may be signed out as "urticaria" or "urticarial hypersensitivity." (See  <a class="medical medical_review" href="/z/d/html/96466.html" rel="external">"Urticarial dermatitis"</a>.)</p><p></p><p class="headingAnchor" id="H2855604571"><span class="h2">Features suggestive of alternative diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic contact dermatitis is the most common condition that may be confused with AD and may occur along with AD. For example, a history of recurrent exacerbations occurring in similar settings (eg, when using a certain topical product or medication or during a particular exposure in a job or recreational situation) suggests concomitant allergic contact dermatitis. (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scabies should be considered if there is a known household exposure. Scabies also often affects the genital area, which is less commonly affected by AD. In older adults, scabies is often associated with recently being in a long-term care facility. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid usually presents with tense bullae and is often localized to areas such as the lower legs. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycosis fungoides is rarely as widespread as adult AD and tends to present with lesions that are well demarcated from normal skin. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="headingAnchor" id="H4276258909"><span class="h1">IDENTIFYING THE CAUSES OF RECALCITRANT DISEASE</span><span class="headingEndMark"> — </span>Many patients with severe adult eczema have had their condition for a long time, often years. The factors underlying an exacerbation of chronic, severe eczema that should be considered and addressed include lack of adherence to treatment, secondary infection, coexisting allergic contact dermatitis, or photosensitive dermatitis [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H4040447507"><span class="h2">Lack of adherence to topical treatment/undertreatment</span><span class="headingEndMark"> — </span>The downsides of topical treatment (messy, time consuming, costly, long term) predictably lead to decreased adherence to treatment over time and persistent or worsening disease. In addition, concerns about adverse effects may lead to inadequate application of the topical medication. Topical corticosteroid phobia, defined as a concern or fear about using topical corticosteroids, is common, with a prevalence among patients and caregivers ranging from 20 to over 80 percent worldwide [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1833559579"><span class="h2">Secondary staphylococcal infection</span><span class="headingEndMark"> — </span>The skin of patients with atopic dermatitis (AD) and other forms of eczema are colonized with <em>Staphylococcus</em> <em>aureus</em> [<a href="#rid19">19</a>]. When a patient with severe eczema has recurrent staphylococcal infections, decolonization should be considered. Frequent bathing with or without bleach, regular use of a chlorinated swimming pool, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> showers, and nasal <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> can all be helpful to reduce carriage [<a href="#rid21">21</a>]. Pets can be carriers of <em>S. aureus</em>, and tubs of creams can be contaminated with bacteria. Often, family members or cohabitating individuals are <em>S. aureus</em> carriers, and treatment of the whole housing unit can stop frequent infections. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Management of infection'</a>.)</p><p class="headingAnchor" id="H344993577"><span class="h2">Allergic contact dermatitis</span><span class="headingEndMark"> — </span>Concurrent allergic contact dermatitis should be considered in all patients with severe AD, as the impaired skin barrier increases the penetration of potential allergens through the skin and the risk of sensitization [<a href="#rid22">22</a>]. Thus, all patients with severe eczema should be patch tested before they are placed on immunosuppressive treatments, which may lead to false-negative results on patch testing. The allergens found in many topical over-the-counter and prescription products (eg, <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a>, corticosteroids, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, propylene glycol) as well as other common allergens (eg, fragrances, preservatives, and nickel) may complicate AD. (See  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p class="headingAnchor" id="H89598066"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Factors that may contribute to the increased severity of AD include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photosensitivity</strong> – When eczematous dermatitis is severe, minimal amounts of ultraviolet (UV) radiation can trigger a flare in some patients. This may be a clue to the diagnosis of photosensitive eczema or may simply be a manifestation of severe dermatitis. In such patients, aggressive photoprotection with good ultraviolet A (UVA) coverage may improve the eczema, while phototherapy will exacerbate it. (See  <a class="medical medical_review" href="/z/d/html/6620.html" rel="external">"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection"</a> and  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental and psychosocial factors</strong> – Exposure to dry climate or sweating can worsen AD. Patients living in a dry environment understandably have more xerosis, resulting in worsening of eczema. In a warm climate and when exercising, some patients may experience increased pruritus and frictional irritation of the skin. Fortunately, most patients with long-standing AD recognize and try to minimize these exposures. Patients often attribute worsening of AD with psychologic stress [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> <strong>deficiency</strong> – Low vitamin D can be associated with increased severity of AD and more frequent skin infections in the patient with AD [<a href="#rid24">24-27</a>].</p><p></p><p class="headingAnchor" id="H2737036986"><span class="h1">APPROACH TO MANAGEMENT</span></p><p class="headingAnchor" id="H3544301031"><span class="h2">Assessment of disease severity and impact on quality of life</span><span class="headingEndMark"> — </span>Patients with severe refractory atopic dermatitis (AD) that has not responded to standard first-line therapies with emollients and topical corticosteroids typically have widespread disease that limits daily activities, psychosocial functioning, and/or sleep, with a considerable, negative impact on quality of life.</p><p>In clinical practice, in addition to visually evaluating the extent and severity of eczema, clinicians may assess the impact of AD on the patient's quality of life by asking open-ended questions on the intensity of symptoms; frequency of flares; and impact of disease on daily activities, psychosocial functioning, and sleep [<a href="#rid19">19</a>]. The burden of treatment, including time spent on treatment, cost of medications, and frequency of health provider visits, should also be assessed.</p><p>Several disease severity scales for AD (eg, the Scoring Atopic Dermatitis [SCORAD] index, the Eczema Area and Severity Index [EASI], the Patient-Oriented Eczema Measure [POEM]) and patient quality-of-life measurement scales have been tested and validated for use in clinical trials, but they are not commonly used in clinical practice and may not accurately identify patients who need more aggressive topical therapies or systemic therapies [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H6021712"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>Patients should be educated about their condition and receive detailed instructions on both the regular treatment of their skin and what to do when flares occur [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhancing adherence</strong> – Educating patients about their condition and how the prescribed treatment is targeted to the causes of their skin inflammation will enhance compliance. To increase adherence to topical regimens, patients should be provided with medications in a vehicle (ie, ointment, cream, or lotion) they like and will actually use. In addition, patients may be instructed to apply the medication only once daily, since there is limited evidence that more frequent treatment is better [<a href="#rid29">29-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addressing cost concerns</strong> – Cost may be reduced by once-daily application and also by diluting the topical corticosteroid with a moisturizer when used under occlusion (eg, wet wraps). These diluted preparations are not stable long term, but for managing an acute flare that requires large volumes of a topical agent used with occlusion, this can lead to substantial savings without reducing efficacy [<a href="#rid33">33,34</a>].</p><p></p><p class="headingAnchor" id="H2110857544"><span class="h2">When is systemic therapy warranted?</span><span class="headingEndMark"> — </span>The decision to start systemic therapies in adults with severe AD that is not controlled by topical therapy is based upon consideration of disease severity, patient's adherence to topical therapies, frequency of flares, and impact on the patient's quality of life [<a href="#rid19">19,35</a>]. Systemic therapy is warranted in the following situations  (<a class="graphic graphic_algorithm graphicRef117349" href="/z/d/graphic/117349.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have persistent, severe disease, despite a trial of intensive topical therapy (see <a class="local">'Intensive topical therapy and phototherapy'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in whom the initial response to intensive topical therapy cannot be maintained with standard topical therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients for whom phototherapy is not feasible or acceptable (see <a class="local">'Phototherapy'</a> below)</p><p></p><p class="headingAnchor" id="H1561365724"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>In adult patients with severe eczema, an improvement (rather than complete clearance) in the signs and symptoms of AD and, especially, a reduction of associated pruritus may be acceptable goals of therapy if the amount of residual disease no longer interferes with daily activities and does not impact the patient's quality of life. As an example, a reduction of approximately 50 percent in pruritus intensity assessed over a period of 24 hours by using the Peak Pruritus Numerical Rating Scale (a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable") can be a reasonable goal in adults with recalcitrant AD [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3183912857"><span class="h1">INTENSIVE TOPICAL THERAPY AND PHOTOTHERAPY</span><span class="headingEndMark"> — </span>Soak and smear/wet wrap topical therapy and phototherapy are appropriate initial therapies in adults with severe dermatitis. They can be used in a stepwise manner or in combination.</p><p class="headingAnchor" id="H3086789357"><span class="h2">Soak and smear/wet wraps</span><span class="headingEndMark"> — </span>A trial of intensive topical therapy (ie, soak and smear or wet wraps) for the initial treatment of patients with severe atopic dermatitis (AD) not controlled by standard topical therapy may be considered in patients who agree to attempt it. These approaches are mainly based on evidence from a limited number of observational studies and low-quality clinical trials in children and adults that have not consistently suggested benefit [<a href="#rid37">37-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Soak and smear</strong> – The patient soaks for 15 minutes in a comfortable tub of water. A high-potency to super high-potency corticosteroid is applied to the whole body, except the groin, axillae, and face, in patients with widespread eczema. In patients with more localized disease, topical corticosteroids may be applied only to affected regions, but the normal skin surrounding the eczematous dermatitis should also be treated. For example, if the eczema is on the lower leg in spots, treat the whole lower leg. Once patients have learned the "soak and smear" approach, they can apply it to break flares of their eczema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wet wrap therapy</strong> – For wet wrap therapy, mid-potency to super-potency steroid preparations (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)), usually in an ointment base, are applied to the involved areas. Super-potent corticosteroids may be diluted with a tolerated moisturizer or petrolatum. The treated areas are then occluded with wet wraps (or moist pajamas covered by dry pajamas). The occlusion should be maintained for a minimum of four hours and should initially occur twice daily. The wet layer should not be allowed to dry up. Such therapy applied by skilled nurses in a daycare setting is particularly effective. Crude <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">coal tar</a> ointment can be added to the topical corticosteroids for additional benefit, although staining and odor are not acceptable to many patients [<a href="#rid41">41,42</a>].</p><p></p><p>Once improvement is achieved, less aggressive topical therapy may control the eczema in some patients. Some experts suggest applying medium- to high-potency topical corticosteroids two to three times per week to normal-appearing skin at sites of frequent flares (proactive therapy) [<a href="#rid19">19</a>]. Those in whom remission cannot be maintained with intermittent use of topical corticosteroids and liberal use of emollients ultimately require a more aggressive approach with phototherapy or systemic therapies.</p><p class="headingAnchor" id="H3156945189"><span class="h2">Phototherapy</span><span class="headingEndMark"> — </span>If available, feasible, and acceptable to the patient, phototherapy is an option for the treatment of severe adult eczema that is not controlled by intensive topical therapy  (<a class="graphic graphic_algorithm graphicRef117349" href="/z/d/graphic/117349.html" rel="external">algorithm 1</a>). Although narrowband ultraviolet B (NBUVB), ultraviolet A1 (UVA1), or psoralen plus ultraviolet A (PUVA; bath or systemic) have been shown to be effective, we prefer NBUVB and UVA1 over PUVA due to their better safety profile [<a href="#rid19">19,43,44</a>].</p><p>Systemic or bath PUVA are treatment options in patients at low risk of skin cancer (skin types 3 to 6  (<a class="graphic graphic_table graphicRef60541" href="/z/d/graphic/60541.html" rel="external">table 3</a>)) and if treatments are infrequent (see  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/z/d/html/91676.html" rel="external">"UVA1 phototherapy"</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Phototherapy is administered two to three times per week initially. The starting doses are generally low and may be administered in combination with aggressive topical treatment as outlined above. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)", section on 'Treatment initiation, frequency, and dose increments'</a> and <a class="local">'Soak and smear/wet wraps'</a> above.)</p><p></p><p class="bulletIndent1">Once weekly or less frequent bath PUVA treatments can control some cases of severe adult eczema. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Bath PUVA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – The use of phototherapy for the treatment of severe AD is supported by several randomized trials and systematic reviews [<a href="#rid44">44-46</a>]. Although the included studies were generally of low quality and heterogeneous regarding the severity assessment criteria, irradiation techniques, and outcome measures, all provided some evidence that NBUVB and UVA1 phototherapy are effective for the treatment of severe AD. Whether UVA1 is preferable to NBUVB for the treatment of acute AD remains uncertain, since most of the studies included in systematic reviews did not specify if patients had chronic, severe AD or acute AD exacerbation. The evidence supporting oral or bath PUVA for the treatment of AD is also limited:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one randomized, eight-week, crossover trial, 47 participants with moderate to severe AD were randomized to receive medium-dose UVA1 or NBUVB three times per week for six weeks [<a href="#rid47">47</a>]. Intention-to-treat analysis showed that the two treatments were equally effective in reducing pruritus and disease severity. Eczema severity (assessed with the Six Area Six Sign Atopic Dermatitis [SASSAD] score) was reduced from the baseline in both study periods by 44 percent in the UVA1 group and by 39 percent in the NBUVB group.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a low-quality, randomized, crossover trial that compared oral PUVA with medium-dose UVA1 for severe, generalized AD, PUVA decreased the severity of disease to a greater extent, led to more rapid improvement, and induced a longer remission period post-treatment [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another small, randomized, half-side comparison study including 12 patients with severe, chronic AD, bath PUVA was as effective as NBUVB in reducing the signs and symptoms of AD (baseline Scoring Atopic Dermatitis [SCORAD] reduction at six weeks was 66 and 64 percent, respectively) [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H835586127"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>The combination of aggressive soak and smear treatment and phototherapy with ultraviolet B (UVB) and crude <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">coal tar</a> (modified Goeckerman regimen) may be helpful in patients for whom phototherapy alone is ineffective. In a small study, five patients with chronic, severe AD unresponsive to NBUVB, broadband UVB, or systemic immunosuppressants were treated in an outpatient setting with daily broadband UVB followed by a topical regimen of crude coal tar and potent or super-potent topical corticosteroids for an average of 27 days [<a href="#rid50">50</a>]. All patients experienced a marked improvement, with an average reduction of the baseline SCORAD score of 75 percent, and remained in remission for 5 to 12 months.</p><p class="headingAnchor" id="H3896757575"><span class="h1">SYSTEMIC THERAPIES</span><span class="headingEndMark"> — </span>Adults with severe, recalcitrant atopic dermatitis (AD) who are not candidates for or do not respond to intensive topical therapy or phototherapy require systemic therapies  (<a class="graphic graphic_algorithm graphicRef117349" href="/z/d/graphic/117349.html" rel="external">algorithm 1</a>) [<a href="#rid19">19,51-53</a>].</p><p>The choice of a systemic treatment depends upon consideration of AD severity, impact on the patient's quality of life, the patient's age and sex, family planning issues, presence of comorbidities, the patient's preferences, and costs. Because some systemic immunosuppressive agents, such as oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and corticosteroids, are all associated with potentially serious adverse effects and require close clinical and laboratory monitoring, candidates for systemic therapy with these agents must be carefully selected. Newer biologic agents, including <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> and <a class="drug drug_general" data-topicid="134704" href="/z/d/drug information/134704.html" rel="external">tralokinumab</a>, have fewer systemic adverse effects and do not require laboratory monitoring. </p><p class="headingAnchor" id="H3849494448"><span class="h2">First-line therapies</span><span class="headingEndMark"> — </span>First-line therapies include biologic drugs that block interleukin (IL) 4 and IL-13 or IL-13 alone. Available options in the United States include <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> and <a class="drug drug_general" data-topicid="134704" href="/z/d/drug information/134704.html" rel="external">tralokinumab</a>. If treatment with a biologic agent is not successful, then treatment with an oral conventional (nontargeted) immunosuppressive agent may be considered.</p><p class="headingAnchor" id="H962473133"><span class="h3">Dupilumab</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> as first-line systemic treatment for adults with severe AD. Dupilumab is an IL-4/13 receptor-alpha antagonist approved by the US Food and Drug Administration (FDA) and European Medicines Agency for the treatment of adults and children older than six months with moderate to severe AD not adequately controlled with topical prescription therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – In adults, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> is initially administered subcutaneously as a loading dose of 600 mg, followed by a maintenance dose of 300 mg every two weeks. Laboratory monitoring is not required. In the author's clinical practice, improvement may be noted in the first month of treatment, but three months or more may be required to achieve maximum benefit. Combining dupilumab with an appropriate topical corticosteroid or other topical agent improves response. Dupilumab has been shown to be associated with a reduced risk of skin infections, including eczema herpeticum [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> for moderate to severe AD in adults and children is supported by several randomized trials [<a href="#rid55">55,56</a>] (see  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'</a>). In one trial, at least a 75 percent improvement from baseline in the Eczema Area and Severity Index (EASI-75) was achieved by approximately 50 percent of patients taking dupilumab compared with approximately 15 percent of patients taking placebo [<a href="#rid55">55</a>]. In a study evaluating the efficacy of dupilumab in 138 consecutive adult patients with difficult-to-treat AD in a real-life setting, treatment with dupilumab for 16 weeks induced a mean reduction in the Eczema Area and Severity Index (EASI) score of 73 percent [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>–<strong> </strong><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> generally has a favorable safety profile.<strong> </strong>Frequent adverse effects of dupilumab include injection site reactions, conjunctivitis (up to 37 percent), and facial redness [<a href="#rid58">58-61</a>]. There have been several reports of inflammatory arthritis and enthesitis associated with dupilumab treatment, in most cases occurring during the first few months of treatment [<a href="#rid62">62-64</a>]. Patients should be counseled about the risk of new-onset joint pain, and that if it occurs, it is generally mild and can be conservatively managed without a need to discontinue dupilumab. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'</a>.)</p><p></p><p class="headingAnchor" id="H1361784051"><span class="h3">Tralokinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134704" href="/z/d/drug information/134704.html" rel="external">Tralokinumab</a> may be an alternative to <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> for severe AD in adults. Tralokinumab is a fully human monoclonal anti-IL-13 antibody approved in Europe and the United States for the treatment of adults with moderate to severe AD that is not adequately controlled with topical prescription therapies [<a href="#rid65">65,66</a>].</p><p><a class="drug drug_general" data-topicid="134704" href="/z/d/drug information/134704.html" rel="external">Tralokinumab</a> is administered subcutaneously as a loading dose of 600 mg once, followed by 300 mg once every other week. Tralokinumab can be used in combination with topical corticosteroids. The efficacy of tralokinumab as monotherapy or in combination with topical corticosteroids has been evaluated in randomized trials [<a href="#rid65">65,66</a>] (see  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Tralokinumab'</a>). Adverse effects of tralokinumab include viral upper respiratory infection, headache, conjunctivitis, and exacerbation of AD.</p><p class="headingAnchor" id="H1981797408"><span class="h2">Second-line therapies</span></p><p class="headingAnchor" id="H3884961826"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is the author's preferred agent for long-term control of severe AD in adult and older adult patients unable or unwilling to use biologic agents and in whom the risk of adverse effects with methotrexate is small:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and monitoring</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is usually administered in a single weekly dose of 7.5 to 25 mg in combination with daily supplementation with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> 1 mg to reduce the risk of several common methotrexate toxicities. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="bulletIndent1">Laboratory monitoring, including complete blood count and renal and liver function, is required (see  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>). New methods for monitoring for liver fibrosis, such as serum amino terminal peptide of type III procollagen and ultrasound-based transient elastography, have reduced the need for liver biopsies [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – The effect of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> usually starts after a few weeks but may be delayed. The maximum benefit is often not seen for several months. Methotrexate is thus not a first-line treatment but is typically started while tapering other therapies (eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or systemic corticosteroids) with rapid onset of action.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – In a small, randomized trial including 42 adults with AD who were unresponsive or intolerant to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> were similarly effective in reducing eczema severity [<a href="#rid69">69</a>]. Patients were treated for 12 weeks and permitted to use topical corticosteroids and oral antihistamines. At the end of 12 weeks, the severity of eczema as assessed by the Scoring Atopic Dermatitis (SCORAD) score decreased by approximately 40 percent in both groups. Treatment was continued by 95 percent of patients in the methotrexate group and 84 percent of patients in the azathioprine group, with reduction in the SCORAD score at 24 weeks of 48 and 43 percent, respectively. Adverse events, none of which were serious, included infections, gastrointestinal upset, and increased liver enzyme levels and occurred in equal proportion in both treatment groups, although lymphocytopenia occurred more frequently in the azathioprine group than in the methotrexate group. Among the 35 patients who continued, interrupted, or switched treatment (reflecting real-life clinical practice) and were followed up at three-month intervals for an additional two years, the clinical response was maintained at two years in both groups (SCORAD index reduced by 63 and 53 percent in the methotrexate and azathioprine groups, respectively) [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H1187020428"><span class="h3">Oral JAK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">Abrocitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> are oral selective Janus kinase (JAK) inhibitors approved in Europe, the United States, and other countries for the treatment of AD in adults whose disease is not controlled with other systemic therapies, including biologics, or when the use of those therapies is not indicated [<a href="#rid71">71-73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">Abrocitinib</a> is given at the dose of 100 mg once daily. For insufficient response after 12 weeks, the dose can be increased to 200 mg once daily.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">Upadacitinib</a> is given at the dose of 15 mg once daily. The dose can be increased to 30 mg once daily if the response is inadequate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">abrocitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> for the treatment of AD is supported by several randomized trials [<a href="#rid71">71,74</a>]. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'JAK inhibitors'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Frequent adverse effects of <a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">abrocitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> reported in AD trials include nausea, acne, headache, nasopharyngitis, and AD flares. Long-term studies of the safety of these agents in patients with AD are lacking. However, based on data from a large, randomized safety trial of patients with rheumatoid arthritis, the US FDA issued a boxed warning for oral JAK inhibitors regarding the increased risk of serious infections, major cardiovascular events (eg, heart attack, stroke), cancer (eg, lymphoma, lung cancer), thrombosis, and death [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H2514179772"><span class="h2">Third-line therapies</span><span class="headingEndMark"> — </span>Third-line therapies include a short course of systemic corticosteroids, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. Due to their adverse effects, these agents should be used for a limited period of time as rescue therapy for immediate relief of acute flares or bridge therapy to other agents relatively safer to use over a prolonged period, if needed [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H3653394780"><span class="h3">Short-term systemic corticosteroids</span><span class="headingEndMark"> — </span>There is a general consensus among experts that systemic corticosteroids should be generally avoided for the management of AD due to adverse effects of prolonged use and risk of rebound flares when interrupted [<a href="#rid76">76</a>]. However, they can occasionally be used for a short period of time in the following circumstances [<a href="#rid76">76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>When other options are not available or contraindicated</p><p class="bulletIndent1"><span class="glyph">●</span>As a bridge therapy to other systemic therapies or phototherapy</p><p class="bulletIndent1"><span class="glyph">●</span>For the immediate relief of acute flares</p><p class="bulletIndent1"><span class="glyph">●</span>In the most severe cases</p><p></p><p>These principles are in agreement with most clinical practice guidelines [<a href="#rid77">77-81</a>]. The dose and duration of a "short course" of systemic corticosteroids have not been determined. The European Task Force on Atopic Dermatitis/European Academy of Dermatology and Venereology Task Force position statement on the treatment of AD suggests that a typical regimen of systemic corticosteroids might be <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 0.5 mg/kg per day for one to two weeks tapered over one month [<a href="#rid79">79</a>]. </p><p>We typically prescribe <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg per day for one week and taper the dose over the following two to three weeks. While systemic corticosteroids are tapered off, patients are transitioned to another systemic agent with a better safety profile (eg, biologics or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) for long-term treatment.</p><p class="headingAnchor" id="H2863917137"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is an option for severe AD in adults who do not have obvious contraindications to its use and who will benefit from a rapid resolution of symptoms [<a href="#rid82">82</a>]. Contraindications to the use of cyclosporine include abnormal renal function, uncontrolled hypertension, uncontrolled infection, and concurrent malignancy (see  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> dose ranges from 2.5 to 5 mg/kg per day. Besides systemic corticosteroids, cyclosporine is the most rapidly acting and effective agent for the management of severe AD. The dermatitis often begins to improve as quickly as within the first week, and the degree of improvement can be dramatic (approaching 100 percent) in eight weeks. Itching improves within days. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment duration</strong> – Long-term use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (ie, beyond one year) is limited by its side effects, mainly hypertension and kidney toxicity, especially in older adults. Moreover, as relapse can be very rapid after discontinuation of treatment, many patients will need to be transitioned to an immunosuppressive agent with a better safety profile while discontinuing cyclosporine. </p><p></p><p class="bulletIndent1">As an example, patients who are stable on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may also be given a low dose of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (eg, 5 to 10 mg per week) for three weeks. The cyclosporine dose is then halved, and the methotrexate dose is increased to 15 to 20 mg per week. After two weeks, cyclosporine is discontinued. During this period of dual immunosuppression, prophylaxis to prevent <em>Pneumocystis</em> pneumonia should be considered. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – The efficacy of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for the treatment of AD is supported by several randomized trials and systematic reviews [<a href="#rid52">52,82-84</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2013 systematic review, 14 trials evaluated the efficacy of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> versus placebo or other systemic immunomodulating agents (eg, intravenous immunoglobulins [IVIGs], <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, MMF) [<a href="#rid84">84</a>]. After short-term treatment ranging from 10 days to 8 weeks, cyclosporine was found to be more effective than placebo in all trials, with a mean improvement from baseline of 50 to 95 percent in different clinical severity scores. In head-to-head trials, cyclosporine was found to be more effective than prednisolone and <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> and as effective as MMF. Higher doses (5 mg/kg per day) induced a more rapid response than lower doses (2.5 to 3 mg/kg per day).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One well-performed, randomized trial compared <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in 38 adults with severe AD [<a href="#rid85">85</a>]. Treatment consisted of a two-week tapering dose of oral prednisolone with a constant daily dose of cyclosporine for six weeks; patients were allowed to use a mid-potency topical corticosteroid, emollients, and oral antihistamines. The authors noted that this regimen reflects a common treatment approach in clinical practice. The primary outcome measure was the proportion of patients with stable remission, defined as improvement in the SCORAD index of at least 50 percent relative to baseline at week 2 in the prednisolone group and week 6 in the cyclosporine group and no flare within a 12-week follow-up. Although the response rate was not significantly different in the two groups at the end of the active treatment period, the relapse rate during the 12-week follow-up was much higher in the prednisolone group than in the cyclosporine group (89 versus 45 percent, respectively).</p><p></p><p class="headingAnchor" id="H59844232"><span class="h3">Mycophenolic acid/mycophenolate mofetil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF)<strong> </strong>and<strong> </strong>mycophenolic acid (MPA) can be considered as treatment options in patients in whom other immunosuppressive agents are not tolerated or are contraindicated. MMF and MPA are usually very well tolerated, and laboratory abnormalities are infrequent. Common adverse effects include fatigue, flu-like symptoms, and gastrointestinal upset. MMF and MPA are typically given at a dose of 1 to 2 g/day and 720 to 1440 mg/day, respectively. The response to treatment is usually delayed, often not seen before six to eight weeks.</p><p>The response to MMF and MPA seems to be dependent on a uridine diphosphate glucuronosyltransferase 1-9 (<em>UGT1A9</em>) polymorphism affecting the metabolism of the medication [<a href="#rid86">86</a>]. Approximately 85 percent of individuals who carry this polymorphism are nonresponders [<a href="#rid86">86</a>]. Patients who respond to treatment usually tolerate long-term therapy, given the relatively good toxicity profile of these agents. Nausea (reduced with enteric-coated <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium [EC-MPS]) is the most common adverse effect. At high doses, usually above 2 g per day, rest tremor can occur. </p><p>The evidence supporting the use of MMF for AD is limited and mainly based upon small, observational studies [<a href="#rid87">87</a>]. No randomized trials have evaluated its efficacy as first-line treatment for severe AD. One small trial compared EC-MPS with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> as a maintenance treatment in 55 adult patients with AD unresponsive to potent topical corticosteroids [<a href="#rid88">88</a>]. All patients were treated for a six-week run-in period with cyclosporine 5 mg/kg per day to achieve rapid remission and then randomized to cyclosporine 3 mg/kg per day or EC-MPS 1440 mg per day for 30 weeks. The severity of eczema, measured using the SCORAD index, was comparable in both study arms until the end of the maintenance phase. After treatment discontinuation, relapse was more rapid in the cyclosporine group than in the EC-MPS group. There were no serious adverse events.</p><p class="headingAnchor" id="H3625098327"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> is an additional option for the treatment of severe AD in adults:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose is 2 to 3 mg/kg. A baseline thiopurine methyltransferase (TPMT) should be performed before initiating the treatment to determine if dose adjustment is required. Clinical response is seen on average in four weeks but may not be seen for six to eight weeks. Long-term use of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> can be associated with lymphopenia, progressive anemia, and transient elevation of liver enzymes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> for the treatment of AD has been evaluated in a few randomized trials [<a href="#rid69">69,89,90</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One small trial including 37 patients with severe AD reported a reduction of 26 percent in the Six Area Six Sign Atopic Dermatitis (SASSAD) score in patients treated with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> compared with 3 percent in patients treated with placebo [<a href="#rid89">89</a>]. However, 16 of 37 patients (43 percent) withdrew from the study. Adverse effects of azathioprine included nausea, vomiting, and gastrointestinal disturbances.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a small, randomized trial including 42 adults with AD, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> were similarly effective in reducing eczema severity [<a href="#rid69">69</a>]. At 12 weeks, both treatments induced a 40 percent reduction of the SCORAD score. (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another trial, 63 patients with active AD not controlled by optimal topical therapy were treated with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (1 mg/kg daily or 2.5 mg/kg daily in patients with reduced or normal TPMT activity, respectively) or placebo [<a href="#rid90">90</a>]. After 12 weeks, the SASSAD score was reduced by 37 percent in the azathioprine group compared with 20 percent in the placebo group. Azathioprine was generally well tolerated. However, two patients developed a drug hypersensitivity reaction.</p><p></p><p class="headingAnchor" id="H2322226133"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112824.html" rel="external">"Society guideline links: Atopic dermatitis"</a>.)</p><p class="headingAnchor" id="H3301553331"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical phenotypes of atopic dermatitis in adults</strong> – In adults, atopic dermatitis (AD; eczema) may present as a chronic, persistent form of childhood AD; a relapsing form of childhood AD that had apparently resolved; or, less commonly, as "adult-onset" AD. (See <a class="local">'Clinical phenotypes in adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient evaluation</strong> – When evaluating an adult patient with <strong>new-onset</strong> dermatitis that is persistent and relapsing, the diagnosis of AD should be made with caution, as a variety of skin conditions may present as an eczematous dermatitis in adulthood  (<a class="graphic graphic_table graphicRef116291" href="/z/d/graphic/116291.html" rel="external">table 1</a>). Once the diagnosis of AD is confirmed, the causes of recalcitrant disease should be considered and addressed. (See <a class="local">'Patient evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to management</strong> – Our approach to the management of adult patients with severe, recalcitrant AD is as follows  (<a class="graphic graphic_algorithm graphicRef117349" href="/z/d/graphic/117349.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest an initial trial of intensive topical therapy with corticosteroids (ie, soak and smear or wet wraps) rather than systemic therapy for patients who agree to attempt it (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Narrowband ultraviolet B (NBUVB) therapy can be an alternative or an adjunct to intensive topical therapy. (See <a class="local">'Intensive topical therapy and phototherapy'</a> above and <a class="local">'Phototherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are unwilling or unable to attempt a trial of intensive topical therapy and/or phototherapy and for those who do not improve with such treatments, we suggest <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> as first-line systemic therapy rather than other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Dupilumab, an interleukin (IL) 4/13 inhibitor, is the treatment of choice for such patients because it has a favorable safety profile, has been shown to be effective in this setting, and can be used for long-term control of symptoms. <a class="drug drug_general" data-topicid="134704" href="/z/d/drug information/134704.html" rel="external">Tralokinumab</a>, an IL-13 inhibitor, may be an alternative to dupilumab. (See <a class="local">'Dupilumab'</a> above and <a class="local">'Tralokinumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients unable or unwilling to use biologic agents and in whom the risk of adverse effects is small, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is the author's preferred agent. Oral <a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">abrocitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> (small molecule Janus kinase [JAK] inhibitors) can be an alternative option. However, due to the increased risk of serious infections, major cardiovascular adverse events, and cancer associated with JAK inhibitors, benefits and risks of treatment should be carefully evaluated in the individual patient. (See <a class="local">'Oral JAK inhibitors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic Dermatitis in Adults: A Diagnostic Challenge. J Investig Allergol Clin Immunol 2017; 27:78.</a></li><li><a class="nounderline abstract_t">Megna M, Patruno C, Balato A, et al. Adult Atopic Dermatitis: Less Certainty, More Challenges. J Investig Allergol Clin Immunol 2017; 27:276.</a></li><li><a class="nounderline abstract_t">Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy 2015; 70:836.</a></li><li><a class="nounderline abstract_t">Megna M, Patruno C, Balato A, et al. An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res 2017; 309:443.</a></li><li><a class="nounderline abstract_t">Silverberg JI. Adult-Onset Atopic Dermatitis. J Allergy Clin Immunol Pract 2019; 7:28.</a></li><li><a class="nounderline abstract_t">Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018; 78:54.</a></li><li><a class="nounderline abstract_t">Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015; 66 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018; 73:1284.</a></li><li><a class="nounderline abstract_t">Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of Atopic Eczema Among Patients Seen in Primary Care: Data From The Health Improvement Network. Ann Intern Med 2019; 170:354.</a></li><li><a class="nounderline abstract_t">Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol 2020; 182:47.</a></li><li><a class="nounderline abstract_t">Kiiski V, Salava A, Susitaival P, et al. Atopic dermatitis in adults: a population-based study in Finland. Int J Dermatol 2022; 61:324.</a></li><li><a class="nounderline abstract_t">Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol 2019; 80:1526.</a></li><li><a class="nounderline abstract_t">Hanifin JM. Adult-Onset Atopic Dermatitis: Fact or Fancy? Dermatol Clin 2017; 35:299.</a></li><li><a class="nounderline abstract_t">Shahriari N, Strober B, Shahriari M. The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging. J Am Acad Dermatol 2020; 83:1533.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Vakharia PP, Chopra R, et al. Phenotypical Differences of Childhood- and Adult-Onset Atopic Dermatitis. J Allergy Clin Immunol Pract 2018; 6:1306.</a></li><li><a class="nounderline abstract_t">Lee HJ, Cho SH, Ha SJ, et al. Minor cutaneous features of atopic dermatitis in South Korea. Int J Dermatol 2000; 39:337.</a></li><li><a class="nounderline abstract_t">Berger TG, Steinhoff M. Pruritus in elderly patients--eruptions of senescence. Semin Cutan Med Surg 2011; 30:113.</a></li><li><a class="nounderline abstract_t">Xu AZ, Tripathi SV, Kau AL, et al. Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus. J Am Acad Dermatol 2016; 74:1017.</a></li><li><a class="nounderline abstract_t">Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol 2017; 77:623.</a></li><li><a class="nounderline abstract_t">Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol 2017; 153:1036.</a></li><li><a class="nounderline abstract_t">Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol 2017; 119:435.</a></li><li><a class="nounderline abstract_t">Rundle CW, Bergman D, Goldenberg A, Jacob SE. Contact dermatitis considerations in atopic dermatitis. Clin Dermatol 2017; 35:367.</a></li><li><a class="nounderline abstract_t">Park H, Kim K. Association of Perceived Stress with Atopic Dermatitis in Adults: A Population-Based Study in Korea. Int J Environ Res Public Health 2016; 13.</a></li><li><a class="nounderline abstract_t">Samochocki Z, Bogaczewicz J, Jeziorkowska R, et al. Vitamin D effects in atopic dermatitis. J Am Acad Dermatol 2013; 69:238.</a></li><li><a class="nounderline abstract_t">Di Filippo P, Scaparrotta A, Rapino D, et al. Vitamin D supplementation modulates the immune system and improves atopic dermatitis in children. Int Arch Allergy Immunol 2015; 166:91.</a></li><li><a class="nounderline abstract_t">van der Schaft J, Ariens LF, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice. J Am Acad Dermatol 2016; 75:1257.</a></li><li><a class="nounderline abstract_t">Albenali LH, Danby S, Moustafa M, et al. Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study. J Allergy Clin Immunol 2016; 138:1715.</a></li><li><a class="nounderline abstract_t">Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70:338.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol 2009; 2:24.</a></li><li><a class="nounderline abstract_t">Viglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res 1990; 18:460.</a></li><li><a class="nounderline abstract_t">Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152:130.</a></li><li><a class="nounderline abstract_t">Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol 2009; 26:551.</a></li><li><a class="nounderline abstract_t">Janmohamed SR, Oranje AP, Devillers AC, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014; 70:1076.</a></li><li><a class="nounderline abstract_t">Wolkerstorfer A, Visser RL, De Waard van der Spek FB, et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol 2000; 143:999.</a></li><li><a class="nounderline abstract_t">James WD, Gutman A, Kirby J. On the utility of soak and smear. J Am Acad Dermatol 2017; 76:e31.</a></li><li><a class="nounderline abstract_t">Kimball AB, Naegeli AN, Edson-Heredia E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:157.</a></li><li><a class="nounderline abstract_t">González-López G, Ceballos-Rodríguez RM, González-López JJ, et al. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2017; 177:688.</a></li><li><a class="nounderline abstract_t">Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006; 154:579.</a></li><li><a class="nounderline abstract_t">Albarrán-Planelles C, Jiménez-Gallo D, Linares-Barrios M, Martínez-Rodríguez A. Our experience with wet-wrap treatment. Actas Dermosifiliogr 2014; 105:e18.</a></li><li><a class="nounderline abstract_t">Gutman AB, Kligman AM, Sciacca J, James WD. Soak and smear: a standard technique revisited. Arch Dermatol 2005; 141:1556.</a></li><li><a class="nounderline abstract_t">van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013; 123:917.</a></li><li><a class="nounderline abstract_t">Slutsky JB, Clark RA, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 2010; 9:1258.</a></li><li><a class="nounderline abstract_t">Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol 2015; 8:511.</a></li><li><a class="nounderline abstract_t">Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170:501.</a></li><li><a class="nounderline abstract_t">Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007; 23:106.</a></li><li><a class="nounderline abstract_t">Pérez-Ferriols A, Aranegui B, Pujol-Montcusí JA, et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr 2015; 106:387.</a></li><li><a class="nounderline abstract_t">Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160:652.</a></li><li><a class="nounderline abstract_t">Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162:655.</a></li><li><a class="nounderline abstract_t">Der-Petrossian M, Seeber A, Hönigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 2000; 142:39.</a></li><li><a class="nounderline abstract_t">Farahnik B, Beroukhim K, Danesh M, et al. Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study. J Am Acad Dermatol 2016; 75:1068.</a></li><li><a class="nounderline abstract_t">Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther (Heidelb) 2017; 7:1.</a></li><li><a class="nounderline abstract_t">Gooderham M, Lynde CW, Papp K, et al. Review of Systemic Treatment Options for Adult Atopic Dermatitis. J Cutan Med Surg 2017; 21:31.</a></li><li><a class="nounderline abstract_t">Hegazy S, Tauber M, Bulai-Livideanu C, et al. Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. J Eur Acad Dermatol Venereol 2017; 31:e423.</a></li><li><a class="nounderline abstract_t">Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol 2018; 78:62.</a></li><li><a class="nounderline abstract_t">Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335.</a></li><li><a class="nounderline abstract_t">Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389:2287.</a></li><li><a class="nounderline abstract_t">Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy 2020; 75:116.</a></li><li><a class="nounderline abstract_t">Ou Z, Chen C, Chen A, et al. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol 2018; 54:303.</a></li><li><a class="nounderline abstract_t">Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol 2022; 86:628.</a></li><li><a class="nounderline abstract_t">Felfeli T, Georgakopoulos JR, Jo CE, et al. Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis. Cornea 2022; 41:1242.</a></li><li><a class="nounderline abstract_t">Muzumdar S, Zubkov M, Waldman R, et al. Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review. J Am Acad Dermatol 2020; 83:1520.</a></li><li><a class="nounderline abstract_t">Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol 2022; 86:708.</a></li><li><a class="nounderline abstract_t">Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep 2022; 21:14.</a></li><li><a class="nounderline abstract_t">Bridgewood C, Wittmann M, Macleod T, et al. T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. J Invest Dermatol 2022; 142:2660.</a></li><li><a class="nounderline abstract_t">Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184:437.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184:450.</a></li><li><a class="nounderline abstract_t">Maurice PD, Maddox AJ, Green CA, et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005; 152:451.</a></li><li><a class="nounderline abstract_t">Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis. World J Hepatol 2017; 9:791.</a></li><li><a class="nounderline abstract_t">Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128:353.</a></li><li><a class="nounderline abstract_t">Roekevisch E, Schram ME, Leeflang MMG, et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. J Allergy Clin Immunol 2018; 141:825.</a></li><li><a class="nounderline abstract_t">Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet 2022; 400:273.</a></li><li><a class="nounderline abstract_t">Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 2021; 384:1101.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397:2151.</a></li><li><a class="nounderline abstract_t">Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396:255.</a></li><li><a class="nounderline abstract_t">Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386:316.</a></li><li><a class="nounderline abstract_t">Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018; 178:768.</a></li><li><a class="nounderline abstract_t">Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327.</a></li><li><a class="nounderline abstract_t">Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26:1176.</a></li><li><a class="nounderline abstract_t">Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30:729.</a></li><li><a class="nounderline abstract_t">Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.</a></li><li><a class="nounderline abstract_t">Saeki H, Nakahara T, Tanaka A, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. J Dermatol 2016; 43:1117.</a></li><li class="breakAll">Nankervis H, Thomas KS, Delamere FM, et al. Scoping Systematic Review of Treatments for Eczema, NIHR Journals Library, 2016.</li><li><a class="nounderline abstract_t">Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21:606.</a></li><li><a class="nounderline abstract_t">Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133:429.</a></li><li><a class="nounderline abstract_t">Schmitt J, Schäkel K, Fölster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010; 162:661.</a></li><li><a class="nounderline abstract_t">Thijs JL, Van Der Geest BAM, Van Der Schaft J, et al. Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J Dermatolog Treat 2017; 28:242.</a></li><li><a class="nounderline abstract_t">Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat 2020; 31:810.</a></li><li><a class="nounderline abstract_t">Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64:1074.</a></li><li><a class="nounderline abstract_t">Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147:324.</a></li><li><a class="nounderline abstract_t">Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839.</a></li></ol></div><div id="topicVersionRevision">Topic 114004 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28071589" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atopic Dermatitis in Adults: A Diagnostic Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28731420" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adult Atopic Dermatitis: Less Certainty, More Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832131" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28432437" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30598180" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adult-Onset Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017738" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925336" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Atopic dermatitis: global epidemiology and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29319189" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of atopic dermatitis in adults: Results from an international survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30508419" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of Atopic Eczema Among Patients Seen in Primary Care: Data From The Health Improvement Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895603" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34510428" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Atopic dermatitis in adults: a population-based study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864464" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28577799" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adult-Onset Atopic Dermatitis: Fact or Fancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32679275" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133223" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phenotypical Differences of Childhood- and Adult-Onset Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849122" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Minor cutaneous features of atopic dermatitis in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767773" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pruritus in elderly patients--eruptions of senescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085236" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803668" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724128" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29150071" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709567" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Contact dermatitis considerations in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472355" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of Perceived Stress with Atopic Dermatitis in Adults: A Population-Based Study in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23643343" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vitamin D effects in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791938" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vitamin D supplementation modulates the immune system and improves atopic dermatitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27846950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27523434" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24290431" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729956" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292327" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656813" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840309" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698702" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069509" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986160" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : On the utility of soak and smear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26852717" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861727" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536797" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657020" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Our experience with wet-wrap treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365257" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Soak and smear: a standard technique revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348739" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941951" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491366" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of atopic dermatitis: safety and efficacy of phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116934" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598862" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phototherapy in the management of atopic dermatitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25728564" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Phototherapy in atopic dermatitis: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120333" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19769631" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651692" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27745637" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025775" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systemic Treatment of Adult Atopic Dermatitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27635033" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Review of Systemic Treatment Options for Adult Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28322469" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987493" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27690741" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28478972" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593343" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182975" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34126094" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843182" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622143" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34022319" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Development of psoriasis during treatment with dupilumab: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35141380" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395222" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000465" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000503" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787813" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28660013" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514637" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized trial of methotrexate versus azathioprine for severe atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29111215" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35871814" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761207" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023008" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711801" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081280" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865094" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813298" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813359" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27004560" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374261" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Atopic dermatitis: a practice parameter update 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076388" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076388" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17447974" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269258" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863501" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27549213" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31294617" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21458107" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174106" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16530578" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
